When asked, patients requested:
ADAPT Study Design:
A study open to a broad range of patients
Patients who test positive for antibodies (AChR, MuSK, or LRP4) and those who test negative for antibodies (seronegative) may be eligible to participate. This is the first phase 3 study for gMG to include seronegative patients.
A therapy designed to target the underlying cause of gMG
Efgartigimod is thought to reduce the presence of antibodies that contribute to neuromuscular weakness in gMG.
To remain on current medications throughout the study
Efgartigimod or placebo will be administered on top of current gMG medications*.
Treatment that accounts for patient’s specific requirements/ needs
Study drug will be given based on physician evaluation of your individual symptoms.
This website requires cookies to provide all of its features and uses tracking technologies. For more information, please see the Website Usage Policies page. If you continue to use this site, you agree with the Terms and Conditions.Learn More